Business Wire06.28.18
Invacare Corporation has appointed Petra Danielsohn-Weil, Ph.D., to its Board of Directors. From 2014 until her retirement in August 2017, Danielsohn-Weil was the regional president for Pfizer Essential Health - Europe, a leader in non-viral anti-infectives, biosimilars, and sterile injectable medicines, and a unit of Pfizer Inc., a research-based, global biopharmaceutical company.
With more than 30 years of experience in the medical and pharmaceutical fields in Europe, Danielsohn-Weil offers deep industry and international expertise. After the board’s extensive search conducted by an internationally recognized executive search firm, Danielsohn-Weil was unanimously appointed by the current members of the board. Her appointment brings the number of Invacare directors to a total of eight, seven of whom are considered independent directors.
“We are pleased to welcome Petra to the Invacare Board of Directors. Petra has a wealth of experience in the European market in commercial development, business integration, R&D, sales, digital marketing, and implementing long-term strategic plans in a complex environment. With our significant operations in Europe, her background and unique experience in emerging markets in the European biotech space will be invaluable as we continue our journey,” said Matthew E. Monaghan, chairman, president and CEO. “Petra will be a great addition to our already strong board, which has considerable healthcare and business experience. Our board continues to evolve into a more diverse, yet focused team with strong leaders to guide us for the future.”
Danielsohn-Weil had served in various general management, regional and global business unit executive roles in Europe and the United States for Pfizer from 2000 until her retirement. Prior to that, she served in various commercial and strategic leadership roles in Europe and the United States for Warner-Lambert from 1988 until its acquisition by Pfizer in 2000. She serves as a board member of NovaMedica LLP, a pharmaceutical company and a portfolio company of Rusnano JSC Corporation. Danielsohn-Weil has an undergraduate degree in educational psychology, a master’s degree in chemistry and biology, and a Ph.D. in biology from the University of Münster in Germany.
“I look forward to joining the Invacare Board of Directors and working with Matt Monaghan, Dr. Martin Harris, lead director, and my colleagues on the board, as we continue through the company’s transformation,” said Danielsohn-Weil.
Invacare Corporation is a manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, distributors and government health services in North America, Europe and Asia/Pacific.
With more than 30 years of experience in the medical and pharmaceutical fields in Europe, Danielsohn-Weil offers deep industry and international expertise. After the board’s extensive search conducted by an internationally recognized executive search firm, Danielsohn-Weil was unanimously appointed by the current members of the board. Her appointment brings the number of Invacare directors to a total of eight, seven of whom are considered independent directors.
“We are pleased to welcome Petra to the Invacare Board of Directors. Petra has a wealth of experience in the European market in commercial development, business integration, R&D, sales, digital marketing, and implementing long-term strategic plans in a complex environment. With our significant operations in Europe, her background and unique experience in emerging markets in the European biotech space will be invaluable as we continue our journey,” said Matthew E. Monaghan, chairman, president and CEO. “Petra will be a great addition to our already strong board, which has considerable healthcare and business experience. Our board continues to evolve into a more diverse, yet focused team with strong leaders to guide us for the future.”
Danielsohn-Weil had served in various general management, regional and global business unit executive roles in Europe and the United States for Pfizer from 2000 until her retirement. Prior to that, she served in various commercial and strategic leadership roles in Europe and the United States for Warner-Lambert from 1988 until its acquisition by Pfizer in 2000. She serves as a board member of NovaMedica LLP, a pharmaceutical company and a portfolio company of Rusnano JSC Corporation. Danielsohn-Weil has an undergraduate degree in educational psychology, a master’s degree in chemistry and biology, and a Ph.D. in biology from the University of Münster in Germany.
“I look forward to joining the Invacare Board of Directors and working with Matt Monaghan, Dr. Martin Harris, lead director, and my colleagues on the board, as we continue through the company’s transformation,” said Danielsohn-Weil.
Invacare Corporation is a manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, distributors and government health services in North America, Europe and Asia/Pacific.
